Recent findings on the brain response to peripheral inflammation have broadened our knowledge on the acute phase response. Notably, such advances may lead to the characterization of acute phase proteins in body fluids other than the blood. Among these, and of particular interest, is the cerebrospinal fluid (CSF) that fills the brain ventricles, the subarachnoid space and the spinal cord.
Acute phase response is a term used to describe, mostly, the liver response to an inflammatory insult, a process that, among other effects, ultimately results in changes in the plasma concentrations of various proteins. The triggers of liver response include the inflammatory insult and the molecules produced by multiple cell types, from inflammatory cells (e.g. neutrophils and macrophages), to endothelial and liver cells. As a consequence, the liver synthesizes a number of so-termed acute phase proteins that are classified, depending on whether their expression is increased or decreased, as positive or negative acute phase response proteins, respectively. Among the positive acute phase proteins are binding proteins, opsonins (e.g. C-reactive protein) and iron-related proteins [e.g. hepcidin (HAMP), ceruloplasmin, lipocalin 2 (LCN2) and ferritin]. The negative acute phase proteins also include binding proteins (e.g. albumin, transthyretin, retinol-binding protein), as well as iron-related proteins (e.g. transferrin). Nonetheless, acute phase response is not a process restricted to the liver. Throughout the years, acute phase proteins expression has also been found altered at the barriers of the brain. Most of these findings originated from work on the brain parenchyma response to inflammation (Quan et al., 1998, Nadeau & Rivest, 1999); however, surprisingly, only recently were the barriers of the brain specifically considered in the overall response to peripheral inflammation. In this chapter we will address the contribution of the barriers of the brain in the acute-phase response to peripheral inflammatory stimuli.
2. The barriers of the brain
For a long time the brain was considered isolated from the immune system and unable to mount an immune response when challenged by invading pathogens. This immune-privileged view of the brain was based on multiple observations: allografts survive longer in the central nervous system (CNS) than in other organs (Fuchs & Bullard, 1988); the CNS lacks both lymphatic vessels and constitutive expression of major histocompatibility complex class I and II molecules on parenchymal cells (Perry, 1998) and, lastly, the CNS was thought to be devoid of classical antigen-presenting cells, such as dendritic cells (Matyszak & Perry, 1996). The assumption of an immune-privileged system was further supported by the discovery of two barriers that confer invaluable protection to the brain: the blood-brain barrier (BBB) and the blood-CSF barrier (BCSFB) (reviewed by Abbott, 2005). While these barriers protect the brain from the fluctuations of blood components that are direct triggers of neuronal function (e.g. amino acids that function as neurotransmitters), it is now clear that they are much more than obstacles to the passage of molecules and cells into and out of the brain. Throughout this chapter we will highlight how both barriers actively participate in brain homeostasis. We will also explore the interplay between the immune and the central nervous systems in physiological and immune-challenged conditions.
2.1. The blood-brain barrier
The BBB is formed by the tight junctions between the endothelial cells of the capillaries that irrigate the brain parenchyma. Additionally, on a larger organizational level, the basal lamina, astrocytic end-feets, pericytes and neurons that surround the central BBB core, altogether make the neurovascular unit (Fig. 1A).
With the exception ofsmall lipophilic molecules, such as O2 and CO2 that freely diffuse across endothelial cells depending on their concentration gradient, the passage of blood-born molecules through the BBB requires the presence of specific transporter or receptor systems. Nutrients, like glucose and amino acids enter the brain through specific transporters, while molecules such as insulin, leptin and transferrin are transported by receptor-mediated endocytosis (Pardridge et al., 1985, Zhang & Pardridge, 2001). Conversely, similar mechanisms constitute a way out of the brain for molecules produced by the brain metabolism,
The brain barriers are needed; the neural milieu must be protected from the drastic concentration changes in blood molecules such as nutrients and ions. Nonetheless, the brain must also be able to rapidly respond to changes, since many of the humoral regulation centers are located within the brain. For these reasons, two brain regions lack the BBB: the circumventricular organs and the choroid plexus (CP). The CP will be addressed below, but we will first briefly describe the circumventricular organs. These brain regions, composed of the area postrema, median eminence, pineal gland, subfornical organ and lamina terminalis, are specialized neuroendocrine sites characterized by their small size and capillary irrigation (fenestration). They can either secrete or constitute sites of action for a variety of different hormones, neurotransmitters and cytokines, for which circumventricular organs are classified as either secretory or sensory, respectively. Compared to other brain regions, except the CP, the circumventricular organs are unique in that they allow exchanges with the periphery. These exchanges are due to the permeability of the endothelium; nonetheless, circumventricular organs do not form an open door into the brain parenchyma given the presence of tight junctions between the tanycytes, the specialized ependymal cells that surround them (Brightman & Kadota, 1992).
2.2. The blood-cerebrospinal fluid barrier
The CP is rapidly and actively exposed to any alteration in the blood milieu. It is formed by a monolayer of epithelial cells that originate from the ependymal cells that line the brain ventricles (two lateral ventricles, and the third and fourth ventricles). The CP’s stroma is highly vascularised and populated by multiple cell types, from fibroblast to macrophages and lymphocytes or neutrophils, in proportions that reflect peripheral conditions (Emerich et al., 2005). The presence of tight junctions in the apical side of the CP’s epithelial cells forms a barrier between the stroma and the CSF that is aptly termed the blood-CSF barrier (BCSFB) (Fig. 2A). Similarly to the BBB, the BCSFB prevents the paracellular passage of molecules and cells from the blood; however, in this case, into to the CSF. Of note, blood flow in the CP’s stroma is up to 10 times higher that of the other brain regions (Johanson et al., 2011). Again, resembling the BBB, the BCSFB also contains transporters and receptors; specifically, their presence in the basolateral and apical sides of the cell membrane allows the controlled passage of molecules in and out of the brain. In particular, the apical side of the epithelial cells faces the CSF and contains numerous villosities, which increase the surface contact area between the blood and the CSF.
The CP’s main function is the production of CSF, which fills the ventricles, the subarachnoid space and the spinal cord (Speake et al., 2001), ensuring an optimal environment for the CNS cells. In the adult human’s CNS there are about 150 mL of circulating CSF that are renewed approximately four times daily (Wright, 1978). The CSF is a clear, slightly viscous fluid that surrounds the CNS and exchanges with the brain interstitial fluid. Given its circulation and exposure it participates in the delivery of nutrients into the brain and also in the removal of waste products generated within the brain. On the other hand, the CSF itself contains few cells and has a protein concentration about 10 times lower than that of the blood (Segal, 2001). The CP generates most of the CSF; the remainder 10-30% is of extrachoroidal origin, mostly from metabolism of the brain parenchyma and from the BBB (Johanson, 2008). Of notice, the CP in itself contributes to the composition of the CSF by secreting several carrier proteins and growth factors (reviewed by Chodobski & Szmydynger-Chodobska, 2001). The high number of mitochondria present in the CP indicates its secretory activity. Additionally, the choroidal CSF secretion relies on the active production of an osmotic gradient that is mainly driven by carbonic anhydrase and Na+/K+ ATPase, and supported by the abundant expression of water channels (aquaporins) on the apical and basaloteral sides (Fig. 2B).
While the CSF system is expected to reflect brain homeostasis, recent evidence has revealed that it also reflects challenges induced in the periphery, including during response to peripheral inflammation which will next be discussed in detail.
3. Acute phase response
The term “acute phase” is associated with alterations in the liver transcription profile that, in response to an acute inflammatory stimulus, is reflected in the concentration of several plasma proteins. Several cells of the immune system also similarly contribute to changes in the concentration of plasma proteins, notably by secreting several cytokines and other immune-modulators that then act on many organ systems, including the CNS. The brain barriers are critical sites for cytokine signal transduction and for the initiation of the brain responses to peripheral inflammation. Circulating cytokines can act on the brain
The subject on whether peripheral inflammation triggers inflammation within the brain has raised the interest of investigators. Of notice, while studying particular events and molecules within the brain parenchyma, several groups have observed staining for various immune-mediators in the brain barriers; among these are tumor necrosis factor-alpha (TNF-a) and interleukin 1-beta (IL1-β) in both CP and BBB endothelial cells (Marques et al., 2007; Nadeau & Rivest 1999; Quan et al., 1999). In addition, “acute phase proteins” can be differently expressed in a tissue-specific manner in response to acute peripheral inflammation. For instance, while peripheral inflammation with the Gram negative bacterial cell wall component lypopolysacharide (LPS) (Dickson et al., 1986; Marques et al., 2007) results in decreased expression of the gene encoding for transthyretin in the liver (Birch & Schreiber, 1986), it does not influence its expression in the CP. This differential response possibly reflects tissue-specific transcription factors regulation (Costa et al., 1990; Yan et al., 1990), while other signal transduction pathways may also be involved.
Despite all evidence on the barriers themselves as a site of homeostasis in response to peripheral stimulus, only recently have they been considered as a whole in mediating or participating in the response to peripheral inflammation. This will be next discussed in detail for the BCSFB, with particular emphasis on the
3.1. The choroid plexus response to acute peripheral inflammation: triggers, mediators and effectors
The CP is ideally equipped to respond to peripheral stimulus and to communicate with the CNS since it is extremely well vascularised and because it produces most of the CSF. In addition, it possesses molecules important for leukocyte adhesion such as, lymphocyte selectin (L-selectin), intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) that are found expressed at low levels in CP epithelial cells and can be up-regulated during inflammation (Endo et al., 1998; Wolburg et al., 1999). As such, the CP is suggested to be one of the first places for cell entry into the brain during inflammatory disease (Reboldi et al., 2009), which will also condition the CSF cell content.
A recent study characterized the complete CP transcriptome in the context of peripheral inflammation induced by a single intraperitoneal injection of LPS (Marques et al., 2009b). These results can be accessed in the GEOdatabase (GSE23714). In this work the kinetic CP transcriptome alterations were evaluated at 1, 3, 6, 12, 24 and 72 h after LPS injection. Interestingly, similarly to the liver, the CP showed a rapid and transient response. Specifically, the CP displayed a response to LPS that peaked between 3 to 6 h after LPS administration and rapidly returned to baseline after 72 h. During this response, the expression of a large number of genes encodes for chemokines (such as chemokine C-C motif ligands 2, 3, 4, 7, 9, 11 and 19 and chemokine C-X-C motif ligands 1, 2, 9, 10, 13 and 16), cytokines (such as IL-1β, IL6 and TNF-α), adhesion molecules (Icam-1, selectin platelet and selection endothelial cell), acute phase proteins (serum amyloid A3, serum amyloid A1 and LCN2), and transporters (amino acid transporters) was altered (Marques et al., 2009b). Interestingly, several well-described pathways recognized to have diverse roles in the regulation of the immune system were also found altered in these conditions. Among these roles, we found the activation of the toll-like receptors (TLRs) and interleukin receptors leading to the subsequent activation of: (i) the transcription factor nuclear factor kappa B (NF-kβ), which regulates the transcription of pro-inflammatory cytokines including TNF-α, IL-1β and IL6; (ii) members of the mitogen-activated proteins kinase family (MAPK), notably p38 and JUN N-terminal kinase (JNK); (iii) the JAK/STAT signalling pathway, and (iv) the transcription factors known as interferon regulatory factors (IRFs) (Miyamoto et al., 1988). Termination of the CP response may be, at least in part, a consequence of the negative feedback inhibition of STAT signalling by SOCS/CIS (Naka et al., 2005), as some of the genes encoding for proteins in this pathway are up-regulated after LPS administration. A similar mechanism has been described in the BBB (Laflamme et al., 1999; Laflamme & Rivest 1999; Lebel et al., 2000). Finally, of notice, the glucocorticoid receptor signalling pathway was also found altered, which is of interest given the role of the hypothalamus/pituitary/adrenal axis in the interplay between the immune and the central nervous systems in sickness behaviour.
Two interesting aspects should be taken into account: the blood-born molecules that trigger the CP response and the impact of the response itself. In this regard, particularly relevant are the molecules secreted into the CSF that ultimately reach and modulate responses within the brain parenchyma. With respect to triggers of the CP response, possible candidate molecules of interest are those that in response to an acute inflammatory stimulus have an increase in their blood concentration. Agents such as LPS, but also intrinsic immune modulators such as cytokines and chemokines, are potential triggers given that, for several of these (e.g. IL-1β, IL-6 and TNF-α), the CP has receptors in the basolateral side of the epithelial cells (Marques et al., 2011). Accordingly,
Our initial work on the mouse CP response to peripheral inflammation, focused on proteins highly expressed and secreted by the CP. Of notice, we observed an increase in the prostaglandin D2 synthase (PTGDS) at 6, 12 and 24 h after peripheral acute injection of LPS, which returned to basal levels at 72 h (Marques et al., 2007) This was accompanied by increased CSF PTGDS concentration (Marques et al., 2007); in agreement with the kinetic profile of increased CSF concentration previously reported in rats after intraperitoneal injection of LPS (Ishizaka et al., 2001). PTGDS catalyzes the isomeration of prostaglandin H2 (PGH2) to produce prostaglandin D2 (PGD2), the major prostanoid in the CNS. Prostaglandin D2 can be transformed into multiple different prostaglandins, which themselves, can display anti- or pro-inflammatory properties. Among this is the conversion of PGD2 into the bioactive cyclopentenone-type prostaglandins of the J2-series such as 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2). By repressing the expression of genes encoding for inflammatory mediators (e.g. TNF-α) 15-dPGJ2 can be considered anti-inflammatory; however it has also been described to have pro-inflammatory through induction of cyclooxygenase 2 (COX-2) (Harris et al., 2002). In the context of the present discussion, the observation that endothelial cells with increased endogenous PGD2 levels downregulate the expression of VCAM-1 (Negoro et al., 2005) is of interest since it may contribute to the resolution of inflammation.
The first step of prostaglandin synthesis occurs through the action of COX-1 or COX-2 on arachidonic acid (AA), originating PGH2, which depending on the enzyme can be next transformed into multiple different prostaglandins. The COX-1 enzyme is ubiquitously expressed, while the COX-2 is mainly involved in inflammatory processes and therefore of particular relevance in the brain response to inflammation. Several studies have shown an increase in COX-2 expressionin the BBB endothelial cells after central or systemic injection of endotoxin or cytokines (Cao et al., 1996; Laflamme et al., 1999). Additionally, the development of selective COX-2 inhibitors further suggests an important role for this cyclooxygenase in the BBB in response to acute inflammation; specifically, its inhibition lead to a decrease in the expression of tight junctions proteins in the endothelial cells of the barrier (Germann et al., 2008). In accordance, it has also been shown that COX-2 null-mice exhibit an increase in LPS-induced BBB disruption, mediated by an increase in matrix metalloproteinases 9 and 3 activities (Choi et al., 2010). These results further support the hypothesis that COX-2 may mediate the neuroinflammatory response, especially in maintaining the integrity of the neurovascular unit (Choi et al., 2010). Finally, cyclooxygenases can differentially modulate leukocyte recruitment into the inflamed brain (Choi et al., 2010). Interestingly, neither COX-1 nor COX-2 expression is altered in the CP transcriptome (that includes the epithelial cells of the BCSFB) in response to peripheral inflammation (Marques et al., 2009b). Altogether, these observations indicate that the BBB and BCSFB responses to inflammation may be different regarding the activation of pathways needed to maintain barrier integrity. Still, any alteration in the permeability properties may render the brain parenchyma more susceptible to noxious molecules and to the infiltration of immune cells. Reflecting the aspect of barrier integrity, it has been shown that a single LPS injection induces down-regulation in the transcripts of tight junction proteins and an increase in those encoding for extracellular matrix remodelling proteins such as metalloproteinases (Marques et al., 2009b).
In summary, the CP displays the adequate anatomical (at the interface between the blood and the CSF) and functional (membrane receptors, signal transduction pathways and secretory) setting to participate in the immune system-brain interplay. The relevance of such occurrence will depend on whether it is reflected in the CSF composition, as is the case for IL-6, CCL-2, PTGDS and LCN2 (Fig. 2C).
3.2. Iron modulation at the brain barriers is part of the acute phase response
While signalling in and out of the brain is currently accepted to occur at the brain barriers, evidence is accumulating on their participation in specific homeostatic circuitries. Particularly interesting is the possibility that the brain barriers participate on regulating brain iron homeostasis, which is relevant in neurodegenerative disorders where accumulation of iron has been reported.
As referred before, the kinetic response of the CP to peripheral inflammation resembles the liver acute phase response, in terms of duration and gene/pathways activation (Marques et al., 2009b). Remarkably, results from our studies show that, in response to inflammation, the CP seems to be a specific site for iron homeostasis. Specifically, it induces the
During an immune response iron metabolism is tightly regulated. This regulation is crucial since iron is an essential element for the body homeostasis. Iron deficiency or excess can lead, respectively, to pathological conditions such as anemia or hemochromatosis. Furthermore, since no mechanism other than bleeding and cell renovation is known for iron excretion, the body maintains a tight iron regulation, although the mechanisms involved in this regulation have only recently been partially characterized. In particular, the liver was identified as the regulatory site for iron homeostasis through the synthesis and secretion of HAMP (Krause et al., 2000). Regulation of iron availability is made by the enterocytes, which determine the quantity of dietary iron that is absorbed. When iron stores are high, iron absorption is blocked; when low, iron absorption increases. This is controlled by the availability of ferroportin (the only iron exporter described), at the basolateral side of the enterocyte, which is regulated by HAMP (Krause et al., 2000). Circulating HAMP binds ferroportin on the surface of enterocytes, leading to its internalization and degradation, and blocking iron absorption into the bloodstream (Nemeth et al., 2004a). Under physiological conditions the level of HAMP is regulated by body iron requirements; however, HAMP expression can be modulated by pro-inflammatory cytokines such as IL-6 and IL-1β during inflammatory response. This represents a host defence mechanism: by decreasing serum iron levels the host decreases iron availability for invading bacteria (Ganz, 2007). It follows that other cells of the body, specifically cells of the immune system, are equipped with the machinery capable of regulating iron homeostasis through the regulation of several iron-related genes and proteins (Porto & De Sousa, 2007). This is significant given the immune cells protective function and role in combating microorganisms. Still, the complete mechanism beyond HAMP regulation is far from fully understood.
The novel concept of regional iron homeostasis regulation, in the context of inflammation, adds another level of complexity to iron homeostasis. If confirmed, local brain iron homeostasis at the barriers might explain why diseases of iron accumulation in the periphery seem to spare the brain (Pientrangel, 2010). In the CP, ferroportin is localized in the apical side of the epithelial cells (Wu et al., 2004) and, in response to peripheral administration of LPS, the CP triggers a transient transcription of the HAMP encoding gene, which may result in inhibition of iron release into the CSF and the brain parenchyma.
In addition, the expression of several other iron-related genes, such as ferritins and ceruloplasmin, are also induced by the inflammatory stimulus. Finally, it should be noted that the stimulation of the
Another well described pathway mediating
Although in-depth studies are necessary to fully characterize the CP’s regulation of iron homeostasis, altogether a mechanism is coming into view. In response to peripheral inflammation, the CP, by secreting HAMP, may trigger the internalization of ferroportin, therefore preventing iron release into the CSF. Concomitantly, it secretes into the CSF other iron-related proteins, such as LCN2 and ceruloplasmin that, by themselves further restrict iron availability for potentially invading microorganisms.
The novel role here proposed for the CP-CSF barrier in regulating iron metabolism may also be present in diseases of the CNS in which iron accumulates or has been described to mediate neuronal toxicity. Among these are Alzheimer’s disease and multiple sclerosis. Of interest, even though in different severity scales, both have underlying inflammatory processes.
4. Conclusion and future perspectives
In the present chapter our goal was to highlight evidence that brain barriers participate in the communication of inflammatory stimuli into the brain. A few aspects, which were not specifically addressed, deserve a final mention, particularly that of neurogenesis and of multiple (or chronical) exposures to acute inflammatory stimuli/events. By modulating the composition of the CSF, or of the interstitial fluid of the brain, inflammatory stimuli induced in the periphery will influence neuronal function and processes such as neurogenesis. In this respect, in adults, LPS has been shown to alter the proliferative and migration profile of brain progenitor cells in the hippocampus (Fujioka & Akema, 2010). Notably, several of the proteins whose concentration is altered in the CSF in response to acute inflammation are recognized as modulators of adult neurogenesis. Future studies will certainly bring us novel clues on the role of neurogenesis as well as its alteration under inflammatory conditions. Also, while the focus of this book is the acute response, it should be mentioned that throughout lifespan, individuals are exposed to several independent acute inflammatory events. It is still unknown how repeated exposure to inflammation may predispose to diseases of the CNS, and how are the barriers of the brain compromised or participants in such response. Nonetheless, it is now known that the response of the CP to repeated prolonged inflammatory stimuli is less drastic and broad than that of a single acute exposure (Marques et al, 2009c). Future studies should further elucidate on how the brain barriers’ attenuate and/or mediate any deleterious effects to normal brain functioning.
The work referenced here was supported by grants from Fundação para a Ciência e a Tecnologia FCT/FEDER (POCTI/SAU-NEU/56618/2004; PTDC/SAU-NEU/105180/2008), and by the DANA Foundation, USA. Fernanda Marques is the recipient of posdoctoral fellowship from FCT (Portugal).
We are grateful to Dr. Nadine Santos for critically reviewing this manuscript.
Abbott N. J. 2005 Dynamics of CNS barriers: evolution, differentiation, and modulation. , 25 1 5 23
Birch H. E. Schreiber G. 1986 Transcriptional regulation of plasma protein synthesis during inflammation., 261 18 8077 8080
Brightman M. W. Kadota Y. 1992 Nonpermeable and permeable vessels of the brain., 120 87 107
Cao C. Matsumura K. Yamagata K. Watanabe Y. 1996 Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever., 733 2 263 272
Ceciliani F. Giordano A. Spagnolo V. 2002 The systemic reaction during inflammation: the acute-phase proteins., 9 3 211 223
Chodobski A. Szmydynger-Chodobska J. 2001 Choroid plexus: target for polypeptides and site of their synthesis., 52 1 65 82
Choi S. H. Aid S. Choi U. Bosetti F. 2010Cyclooxygenases-1 and-2 differentially modulate leukocyte recruitment into the inflamed brain. , 10 5 448 457, 1473-1150
Costa R. H. Van Dyke T. A. Yan C. Kuo F. Darnell J. E. Jr 1990 Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus. , 87 17 6589 6593, 0027-8424
Dantzer R. 2001 Cytokine-induced sickness behavior: mechanisms and implications., 933 222 234
Dantzer R. O’Connor J. C. Freund G. G. Johnson R. W. Kelley K. W. 2008 From inflammation to sickness and depression: when the immune system subjugates the brain. , 9 1 46 56
Dickson P. W. Aldred A. R. Marley P. D. Bannister D. Schreiber G. 1986 Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver., 261 8 3475 3478
Emerich D. F. Skinner S. J. Borlongan C. V. Vasconcellos A. V. Thanos C. G. 2005 The choroid plexus in the rise, fall and repair of the brain. , 27 3 262 274
Endo H. Sasaki K. Tonosaki A. Kayama T. 1998 Three-dimensional and ultrastructural ICAM-1 distribution in the choroid plexus, arachnoid membrane and dural sinus of inflammatory rats induced by LPS injection in the lateral ventricles., 793 1-2, 297 301
Engelhardt B. 2006 Regulation of immune cell entry into the central nervous system., 43 259 280
Engelhardt B. Coisne C. 2011 Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle., 8 1 4 2045-8118
Flo T. H. Smith K. D. Sato S. Rodriguez D. J. Holmes M. A. Strong R. K. Akira S. Aderem A. 2004 Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron., 432 7019 917 921
Fuchs H. E. Bullard D. E. 1988 Immunology of transplantation in the central nervous system., 51 6 278 296
Fujioka H. Akema T. 2010 Lipopolysaccharide acutely inhibits proliferation of neural precursor cells in the dentate gyrus in adult rats. , 1352 35 42
Funk C. D. 2001 Prostaglandins and leukotrienes: advances in eicosanoid biology. , 294 5548 1871 1875, 0036-8075
Furuyashiki T. Narumiya S. 2009 Roles of prostaglandin E receptors in stress responses. , 9 1 31 38, 1471-4892
Gabay C. Kushner I. 1999 Acute-phase proteins and other systemic responses to inflammation., 340 6 448 454
Gaillard R. C. 1998 Cytokines in the neuroendocrine system., 17 1-4, 181 216
Ganz T. 2007 Molecular control of iron transport. , 18 2 394 400
Germann B. Neuhaus W. Hofer-Warbinek R. Noe C. R. 2008 Applying blood-brain barrier in vitro models to study the influence of drugs on endothelial cells-effects of selected COX-inhibitors., 63 4 303 307, 0031-7144
Hanly A. Petito C. K. 1998 HLA-DR-positive dendritic cells of the normal human choroid plexus: a potential reservoir of HIV in the central nervous system., 29 1 88 93
Harris S. G. Padilla J. Koumas L. Ray D. Phipps R. P. 2002).Prostaglandins as modulators of immunity. , 23 23 144 150
Hosoi T. Okuma Y. Nomura Y. 2002 The mechanisms of immune-to-brain communication in inflammation as a drug target. 1 3 257 262
Ishizaka M. Ohe Y. Senbongi T. Wakabayashi K. Ishikawa K. 2001 Inflammatory stimuli increase prostaglandin D synthase levels in cerebrospinal fluid of rats., 12 6 1161 1165,
Johanson C. E. Duncan J.A. 3rd Klinge P. M. Brinker T. Stopa E. G. Silverberg G. D. 2008Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Research, 5 10 1743-8454
Johanson C. E. Stopa E. G. Mc Millan P. N. 2011 The blood-cerebrospinal fluid barrier: structure and functional significance., 686 101 131, 1940-6029
Kemna E. Pickkers P. Nemeth E. van der Hoeven H. Swinkels D. 2005 Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS., 106 5 1864 1866
Kjeldsen L. Cowland J. B. Borregaard N. 2000 Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse., 1482 1-2, 272 283, 0006-3002
Krause A. Neitz S. Magert H. J. Schulz A. Forssmann W. G. Schulz-Knappe P. Adermann K. 2000 LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity., 480 2-3, 147 150
Laflamme N. Lacroix S. Rivest S. 1999 An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia., 19 24 10923 10930
Laflamme N. Rivest S. 1999 Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain., 73 1 309 321
Lebel E. Vallieres L. Rivest S. 2000 Selective involvement of interleukin-6 in the transcriptional activation of the suppressor of cytokine signaling-3 in the brain during systemic immune challenges., 141 10 3749 3763
Ling E. A. Kaur C. Lu J. 1998Origin, nature, and some functional considerations of intraventricular macrophages, with special reference to the epiplexus cells. , 41 1 43 56
Liu Q. Nilsen-Hamilton M. 1995 Identification of a new acute phase protein. , 270 38 22565 22570
Marques F. Falcao A. M. Sousa J. C. Coppola G. Geschwind D. Sousa N. Correia-Neves M. Palha J. A. 2009a Altered iron metabolism is part of the choroid plexus response to peripheral inflammation. , 150 6 2822 2828, 1945-7170
Marques F. Rodrigues A. J. Sousa J. C. Coppola G. Geschwind D. H. Sousa N. Correia-Neves M. Palha J. A. 2008 Lipocalin 2 is a choroid plexus acute-phase protein. 28 3 450 455,
Marques F. Sousa J. C. Coppola G. Falcao A. M. Rodrigues A. J. Geschwind D. H. Sousa N. Correia-Neves M. Palha J. A. 2009b Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. , 29 5 921 932
Marques F. Sousa J. C. Coppola G. Gao F. Puga R. Brentani H. Geschwind D. H. Sousa N. Correia-Neves M. Palha J. A. 2011 Transcriptome signature of the adult mouse choroid plexus., 8 1 10 2045-8118
Marques F. Sousa J. C. Coppola G. Geschwind D. H. Sousa N. Palha J. A. Correia-Neves M. 2009c The choroid plexus response to a repeated peripheral inflammatory stimulus., 10 135 1471-2202
Marques F. Sousa J. C. Correia-Neves M. Oliveira P. Sousa N. Palha J. A. 2007 The choroid plexus response to peripheral inflammatory stimulus. , 144 2 424 430
Matyszak M. K. Perry V. H. 1996 The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system., 74 2 599 608
Mc Menamin P. G. 1999Distribution and phenotype of dendritic cells and resident tISSNue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. , 405 4 553 562
Miyamoto M. Fujita T. Kimura Y. Maruyama M. Harada H. Sudo Y. Miyata T. Taniguchi T. 1988 Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements., 54 6 903 913
Nadeau S. Rivest S. 1999 Regulation of the gene encoding tumor necrosis factor alpha (TNF-alpha) in the rat brain and pituitary in response in different models of systemic immune challenge., 58 1 61 77
Naka T. Fujimoto M. Tsutsui H. Yoshimura A. 2005 Negative regulation of cytokine and TLR signalings by SOCS and others., 87 61 122
Negoro H. Shin W. S. Hakamada-Taguchi R. Eguchi N. Urade Y. Goto A. Toyo-Oka T. Fujita T. Omata M. Uehara Y. 2005Endogenous prostaglandin D(2) synthesis decreases vascular cell adhesion molecule-1 expression in human umbilical vein endothelial cells. , 78 22 29
Nemeth E. Rivera S. Gabayan V. Keller C. Taudorf S. Pedersen B. K. Ganz T. 2004a IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin., 113 9 1271 1276
Nemeth E. Tuttle M. S. Powelson J. Vaughn M. B. Donovan A. Ward D. M. Ganz T. Kaplan J. 2004b Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. , 306 5704 2090 2093
Nemeth E. Valore E. V. Territo M. Schiller G. Lichtenstein A. Ganz T. 2003Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. , 101 7 2461 2463
Pardridge W. M. Eisenberg J. Yang J. 1985 Human blood-brain barrier insulin receptor., 44 6 1771 1778
Perry V. H. 1998 A revised view of the central nervous system microenvironment and major histocompatibility complex class II antigen presentation., 90 2 113 121
Pientrangelo A. 2010Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. , 139 2 393 408
Porto G. De Sousa M. 2007 Iron overload and immunity., 13 35 4707 4715
Quan N. Stern E. L. Whiteside M. B. Herkenham M. 1999 Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. , 93 1-2, 72 80
Quan N. Whiteside M. Herkenham M. 1998 Time course and localization patterns of interleukin-1beta messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide., 83 1 281 293
Reboldi A. Coisne C. Baumjohann D. Benvenuto F. Bottinelli D. Lira S. Uccelli A. Lanzavecchia A. Engelhardt B. Sallusto F. 2009C-C chemokine receptor 6-regulated entry of T(H)-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. , 514 523
Saper C. B. Breder C. D. 1992 Endogenous pyrogens in the CNS: role in the febrile response., 93 419 428; discussion 428-419, 0079-6123
Saper C. B. Breder C. D. 1994 The neurologic basis of fever., 330 26 1880 1886, 0028-4793
Segal M. B. 2001 Transport of nutrients across the choroid plexus., 52 1 38 48
Speake T. Whitwell C. Kajita H. Majid A. Brown P. D. 2001 Mechanisms of CSF secretion by the choroid plexus., 52 1 49 59
Sunil V. R. Patel K. J. Nilsen-Hamilton M. Heck D. E. Laskin J. D. Laskin D. L. 2007 Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. , 177 187
Verga Falzacappa. M. V. Casanovas G. Hentze M. W. Muckenthaler M. U. 2008A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. , 531 540
Verma S. Nakaoke R. Dohgu S. Banks W. A. 2006 Release of cytokines by brain endothelial cells: A polarized response to lipopolysaccharide. , 20 5 449 455, 0889-1591
Wang R. H. Li C. Xu X. Zheng Y. Xiao C. Zerfas P. Cooperman S. Eckhaus M. Rouault T. Mishra L. Deng C. X. 2005 A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression., 2 6 399 409
Wolburg K. Gerhardt H. Schulz M. Wolburg H. Engelhardt B. 1999 Ultrastructural localization of adhesion molecules in the healthy and inflamed choroid plexus of the mouse., 296 2 259 269
Wright E. M. 1978 Transport processes in the formation of the cerebrospinal fluid., Biochemistry & Pharmacology, 83 3 34
Wu L. J. Leenders A. G. Cooperman S. Meyron-Holtz E. Smith S. Land W. Tsai R. Y. Berger U. V. Sheng Z. H. Rouault T. A. 2004 Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier., 1001 1-2, 108 117
Yan C. Costa R. H. Darnell J. E. Jr Chen J. D. Van Dyke T. A. 1990 Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice., 9 3 869 878
Zhang Y. Pardridge W. M. 2001 Rapid transferrin efflux from brain to blood across the blood-brain barrier., 76 5 1597 1600